Drug Approval | April 29, 2025
IOL Chemicals and Pharmaceuticals receives approval CDE of NMPA, China for Ibuprofen
This approval authorizes the company to export Ibuprofen to the Chinese markets
This approval authorizes the company to export Ibuprofen to the Chinese markets
USFDA inspection at Alembic Pharma's Bioequivalence facility
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
Total Income in Q2 FY25 stood at Rs. 532.18 crore
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Subscribe To Our Newsletter & Stay Updated
